Cargando…

TLR5 agonists enhance anti-tumor immunity and overcome resistance to immune checkpoint therapy

Primary and adaptive resistance to immune checkpoint therapies (ICT) represent a considerable obstacle to achieving enhanced overall survival. Innate immune activators have been actively pursued for their antitumor potential. Herein we report that a syngeneic 4T1 mammary carcinoma murine model for e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gonzalez, Caleb, Williamson, Sarah, Gammon, Seth T., Glazer, Sarah, Rhee, Joon Haeng, Piwnica-Worms, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9837180/ https://www.ncbi.nlm.nih.gov/pubmed/36635337 http://dx.doi.org/10.1038/s42003-022-04403-8

Ejemplares similares

Inhibition of myeloperoxidase enhances immune checkpoint therapy for melanoma
por: Liu, Tracy W, et al.
Publicado: (2023)

Multi-Modal Multi-Spectral Intravital Microscopic Imaging of Signaling Dynamics in Real-Time during Tumor–Immune Interactions
por: Liu, Tracy W., et al.
Publicado: (2021)

Multi-Modal Multi-Spectral Intravital Macroscopic Imaging of Signaling Dynamics in Real Time during Tumor–Immune Interactions
por: Liu, Tracy W., et al.
Publicado: (2021)

Evaluation of (89)Zr-Labeled Anti-PD-L1 Monoclonal Antibodies Using DFO and Novel HOPO Analogues as Chelating Agents for Immuno-PET
por: Radaram, Bhasker, et al.
Publicado: (2023)

Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade
por: Lee, Won Suk, et al.
Publicado: (2022)

DSP-0509, a systemically available TLR7 agonist, exhibits combination effect with immune checkpoint blockade by activating anti-tumor immune effects
por: Ota, Yosuke, et al.
Publicado: (2023)

Single-Cell Resolution Imaging of Retinal Ganglion Cell Apoptosis In Vivo Using a Cell-Penetrating Caspase-Activatable Peptide Probe
por: Qiu, Xudong, et al.
Publicado: (2014)

Excess exogenous pyruvate inhibits lactate dehydrogenase activity in live cells in an MCT1-dependent manner
por: Rao, Yi, et al.
Publicado: (2021)

TLR4, 5, and 9 Agonists Inhibit Murine Airway Invariant Natural Killer T Cells in an IL-12-Dependent Manner
por: Shim, Jae-Uoong, et al.
Publicado: (2012)

Dendritic cell vaccination with a toll-like receptor agonist derived from mycobacteria enhances anti-tumor immunity
por: Vo, Manh-Cuong, et al.
Publicado: (2015)

OMV Vaccines and the Role of TLR Agonists in Immune Response
por: Mancini, Francesca, et al.
Publicado: (2020)

TLR2 – an innate immune checkpoint in multiple sclerosis
por: Hossain, Md Jakir, et al.
Publicado: (2015)

Apoptosis Detection in Retinal Ganglion Cells Using Quantitative Changes in Multichannel Fluorescence Colocalization
por: Qiu, Xudong, et al.
Publicado: (2022)

A TLR9 agonist enhances the anti-tumor immunity of peptide and lipopeptide vaccines via different mechanisms
por: Song, Ying-Chyi, et al.
Publicado: (2015)

In situ immunization of a TLR9 agonist virus-like particle enhances anti-PD1 therapy
por: Cheng, Yinwen, et al.
Publicado: (2020)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
por: Kiaie, Seyed Hossein, et al.
Publicado: (2023)

Axonal Transport as an In Vivo Biomarker for Retinal Neuropathy
por: Le Roux, Lucia G., et al.
Publicado: (2020)

Alum Adjuvant and Built-in TLR7 Agonist Synergistically Enhance Anti-MUC1 Immune Responses for Cancer Vaccine
por: Zhou, Shi-Hao, et al.
Publicado: (2022)

A Super TLR Agonist to Improve Efficacy of Dendritic Cell Vaccine in Induction of Anti-HCV Immunity
por: Hong, Bangxing, et al.
Publicado: (2012)

Flagellin-dependent TLR5/caveolin-1 as a promising immune activator in immunosenescence
por: Lim, Jae Sung, et al.
Publicado: (2015)

A TLR4 agonist improves immune checkpoint blockade treatment by increasing the ratio of effector to regulatory cells within the tumor microenvironment
por: Farias, A., et al.
Publicado: (2021)

Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade
por: Marchini, Antonio, et al.
Publicado: (2016)

Overcoming Immunotherapy Resistance With Radiation Therapy and Dual Immune Checkpoint Blockade
por: Davidson, Tara, et al.
Publicado: (2022)

Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
por: Xie, Qingqing, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
por: Lao, Yefang, et al.
Publicado: (2022)

Correction: Nano-immunotherapy: overcoming delivery challenge of immune checkpoint therapy
por: Kiaie, Seyed Hossein, et al.
Publicado: (2023)

Resistance of melanoma to immune checkpoint inhibitors is overcome by targeting the sphingosine kinase-1
por: Imbert, Caroline, et al.
Publicado: (2020)

Modulation of Innate Immune Responses via Covalently Linked TLR Agonists
por: Tom, Janine K., et al.
Publicado: (2015)

Effects of TLR agonists on immune responses in Trichinella spiralis infected mice
por: Tang, Bin, et al.
Publicado: (2020)

Rewiring innate and adaptive immunity with TLR9 agonist to treat osteosarcoma
por: Cascini, Caterina, et al.
Publicado: (2023)

Alum and a TLR7 agonist combined with built-in TLR4 and 5 agonists synergistically enhance immune responses against HPV RG1 epitope
por: Mashhadi Abolghasem Shirazi, Maryam, et al.
Publicado: (2023)

Recombinant TLR5 Agonist CBLB502 Promotes NK Cell-Mediated Anti-CMV Immunity in Mice
por: Hossain, Mohammad S., et al.
Publicado: (2014)

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
por: Lemos, Henrique, et al.
Publicado: (2020)

Conjugate of ibrutinib with a TLR7 agonist suppresses melanoma progression and enhances antitumor immunity
por: Ren, Sumei, et al.
Publicado: (2022)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Targeting the antigen processing and presentation pathway to overcome resistance to immune checkpoint therapy
por: D’Amico, Silvia, et al.
Publicado: (2022)

Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance
por: Zhou, Xiaoting, et al.
Publicado: (2022)

Overcoming Resistance to Immune Checkpoint Inhibitor Therapy Using Calreticulin-Inducing Nanoparticle
por: Chandrasekar, Sri Vidhya, et al.
Publicado: (2023)

Overcoming immune checkpoint blockade resistance in solid tumors with intermittent ITK inhibition
por: Zhao, Manzhi, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_i7dqq7p00pate79o9c9h0d7560